Onconox Inc. Appoints Professor Justin Stebbing as Scientific and Medical Advisor to Support the Advancement of OCN001

Summary

Onconox Inc. has appointed Professor Justin Stebbing, a leading global oncologist, as Scientific and Medical Advisor to help shape the company’s scientific and clinical strategy for OCN001. His expertise strengthens Onconox’s preparations for IND-enabling activities and future clinical development. Both CEO Dr Sitaram Velaga and Professor Stebbing commented on the importance of this appointment.

Onconox Inc., a biotechnology company dedicated to developing a novel therapeutic candidate for lung cancer, today announced the appointment of Professor Justin Stebbing as Scientific and Medical Advisor. Professor Stebbing will support the company in shaping its scientific, translational, and clinical development strategy as OCN001 advances toward IND submission and future clinical evaluation.

A globally recognized oncologist and academic, Professor Stebbing brings extensive experience across drug development, translational oncology, and clinical strategy. His expertise strengthens Onconox’s efforts to build on the significant preclinical progress already achieved and to prepare a robust framework for its planned regulatory and clinical milestones.

Dr Sitaram Velaga, CEO of Onconox Inc., commented:"We are delighted to welcome Professor Stebbing to Onconox. His scientific insight and clinical perspective will be invaluable as we prepare OCN001 for its next stages of development. Having someone of Justin’s caliber involved at this early phase strengthens our confidence as we refine the program’s scientific direction and progress toward IND submission."

Professor Justin Stebbing added:"OCN001 represents a compelling opportunity to address a major unmet need in lung cancer. I am pleased to support Onconox at this pivotal stage and look forward to working with Sitaram and the team to help navigate the scientific, translational, and clinical questions that will guide the asset toward first-in-human studies."

Professor Stebbing’s appointment marks another milestone in Onconox’s early development, following its spin-out from Kenox Pharmaceuticals and the completion of its seed funding round. His involvement enhances the company’s scientific depth as it advances OCN001 through the remaining IND-enabling activities.

Further updates on Onconox’s progress will be provided as development milestones are achieved.